Nurix Therapeutics (NRIX) EBT: 2019-2025
Historic EBT for Nurix Therapeutics (NRIX) over the last 6 years, with Aug 2025 value amounting to -$86.4 million.
- Nurix Therapeutics' EBT fell 76.82% to -$86.4 million in Q3 2025 from the same period last year, while for Aug 2025 it was -$244.0 million, marking a year-over-year decrease of 38.09%. This contributed to the annual value of -$193.3 million for FY2024, which is 34.28% down from last year.
- Latest data reveals that Nurix Therapeutics reported EBT of -$86.4 million as of Q3 2025, which was down 102.37% from -$42.7 million recorded in Q2 2025.
- In the past 5 years, Nurix Therapeutics' EBT ranged from a high of -$24.2 million in Q1 2021 and a low of -$86.4 million during Q3 2025.
- For the 3-year period, Nurix Therapeutics' EBT averaged around -$47.5 million, with its median value being -$42.7 million (2025).
- In the last 5 years, Nurix Therapeutics' EBT slumped by 101.76% in 2021 and then soared by 46.53% in 2023.
- Nurix Therapeutics' EBT (Quarterly) stood at -$37.7 million in 2021, then declined by 24.06% to -$46.7 million in 2022, then increased by 10.19% to -$42.0 million in 2023, then tumbled by 39.53% to -$58.5 million in 2024, then tumbled by 76.82% to -$86.4 million in 2025.
- Its EBT was -$86.4 million in Q3 2025, compared to -$42.7 million in Q2 2025 and -$56.4 million in Q1 2025.